Experian Health's State of Claims survey finds 40% of providers have at least 10% of their claims denied, and only 30% recover most of that lost revenue.
|Videos|March 29, 2022
The future of COVID-19 testing
Author(s)Chris Mazzolini
What the BA.2 variant, the ending of mask mandates and allergy season means for COVID-19 testing.
Advertisement
COVID-19 is on the rise again. At the same time many mask and social distancing mandates are ending. And, lastly, allergy season is upon us, which means many of your patients may be unsure if they have COVID-19 or allergy symptoms.
To discuss these trends, Medical Economics sat down with Joseph Mann, MSN, FNP-C, of BD Life Sciences. Watch the interview below.
Advertisement
Related to this article
CKD is growing as a global health problem, but screenings and treatments aren't reaching patients who need them.
The top news stories in medicine this week.
CMS' 2027 proposal fixes the quality list, but the roster still spins.
Payer enrollment rarely lines up with a new physician’s first day. A week-by-week plan helps practices avoid a revenue gap, handle pending claims and know when the schedule can safely open.
Clinical enthusiasm doesn't equal a purchase order, and device makers need a case that wins over both clinicians and hospital buyers early in development.
Blue Cross and Blue Shield of Texas is leaving Medicare Advantage, and several Florida systems are splitting with UnitedHealthcare. Here's what changes by state before the Dec. 7 deadline.
In three online experiments, adults who would have to pay for a procedure out of pocket were less likely to schedule it, and the anxiety the cost caused raised the pain they expected.
Advertisement
Advertisement
Trending on Medical Economics
1
Blue Cross and Blue Shield of Texas leaves Medicare Advantage as UnitedHealthcare splits with Florida health systems
2
Why routine kidney screening in primary care is a clinical and financial necessity
3
Medicare is still swiping left on your patients
4
Why are claims being denied in 2026? 'Services not covered' now tops the list
5